Go Pro
→ Your book is inside (From Profits Run) (Ad)tc pixel Free CYCN Stock Alerts

Cyclerion Therapeutics (CYCN) Competitors

Cyclerion Therapeutics logo
$3.79 -0.12 (-3.07%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$3.88 +0.09 (+2.48%)
As of 08/14/2026 05:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CYCN vs. SPRO, CING, HRTX, MNOV, and TENX

Should you buy Cyclerion Therapeutics stock or one of its competitors? Cyclerion Therapeutics's main competitors and comparable companies include Spero Therapeutics (SPRO), Cingulate (CING), Heron Therapeutics (HRTX), MediciNova (MNOV), and Tenax Therapeutics (TENX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cyclerion Therapeutics compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Spero Therapeutics has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

Spero Therapeutics has higher revenue and earnings than Cyclerion Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spero Therapeutics$66.80M1.07$8.57M$0.1111.18
Cyclerion Therapeutics$2.07M8.57-$3.53M-$1.66N/A

In the previous week, Spero Therapeutics had 8 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 9 mentions for Spero Therapeutics and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.89 beat Spero Therapeutics' score of 0.87 indicating that Cyclerion Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Spero Therapeutics Positive
Cyclerion Therapeutics Very Positive

Spero Therapeutics has a net margin of 24.90% compared to Cyclerion Therapeutics' net margin of -170.11%. Spero Therapeutics' return on equity of 16.17% beat Cyclerion Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Spero Therapeutics24.90% 16.17% 12.57%
Cyclerion Therapeutics -170.11%-87.96%-74.86%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spero Therapeutics
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Spero Therapeutics beats Cyclerion Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Cingulate?

Cyclerion Therapeutics (NASDAQ:CYCN) and Cingulate (NASDAQ:CING) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Cingulate had 8 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 9 mentions for Cingulate and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.89 beat Cingulate's score of 1.05 indicating that Cyclerion Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cyclerion Therapeutics Very Positive
Cingulate Positive

Cingulate has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -87.96% beat Cingulate's return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclerion Therapeutics-170.11% -87.96% -74.86%
Cingulate N/A -347.67%-153.02%

Cyclerion Therapeutics has higher revenue and earnings than Cingulate. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclerion Therapeutics$2.07M8.57-$3.53M-$1.66N/A
CingulateN/AN/A-$22.45M-$3.59N/A

Cingulate has a consensus target price of $27.33, suggesting a potential upside of 437.00%. Given Cingulate's stronger consensus rating and higher possible upside, analysts plainly believe Cingulate is more favorable than Cyclerion Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cingulate
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

75.6% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 34.3% of Cyclerion Therapeutics shares are held by insiders. Comparatively, 5.3% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cyclerion Therapeutics has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Cingulate has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market.

Summary

Cyclerion Therapeutics beats Cingulate on 9 of the 15 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Cyclerion Therapeutics has lower revenue, but higher earnings than Heron Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$151.18M0.42-$20.19M-$0.19N/A
Cyclerion Therapeutics$2.07M8.57-$3.53M-$1.66N/A

Heron Therapeutics currently has a consensus price target of $2.00, suggesting a potential upside of 494.00%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Heron Therapeutics is more favorable than Cyclerion Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heron Therapeutics
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Heron Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

In the previous week, Heron Therapeutics had 19 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 20 mentions for Heron Therapeutics and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.89 beat Heron Therapeutics' score of -0.31 indicating that Cyclerion Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Heron Therapeutics Neutral
Cyclerion Therapeutics Very Positive

Heron Therapeutics has a net margin of -22.52% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -87.96% beat Heron Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Heron Therapeutics-22.52% -293.02% -10.00%
Cyclerion Therapeutics -170.11%-87.96%-74.86%

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Heron Therapeutics beats Cyclerion Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to MediciNova?

Cyclerion Therapeutics (NASDAQ:CYCN) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

In the previous week, MediciNova had 5 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 6 mentions for MediciNova and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.89 beat MediciNova's score of 0.75 indicating that Cyclerion Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cyclerion Therapeutics Very Positive
MediciNova Positive

Cyclerion Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

Cyclerion Therapeutics has a net margin of -170.11% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -25.81% beat Cyclerion Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclerion Therapeutics-170.11% -87.96% -74.86%
MediciNova -1,168.70%-25.81%-23.74%

MediciNova has a consensus target price of $8.33, indicating a potential upside of 536.13%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than Cyclerion Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
MediciNova
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67

Cyclerion Therapeutics has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Cyclerion Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclerion Therapeutics$2.07M8.57-$3.53M-$1.66N/A
MediciNova$920.48K70.05-$12M-$0.21N/A

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Comparatively, 14.0% of MediciNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

MediciNova beats Cyclerion Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Tenax Therapeutics?

Cyclerion Therapeutics (NASDAQ:CYCN) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Tenax Therapeutics has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Tenax Therapeutics' return on equity of -61.54% beat Cyclerion Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclerion Therapeutics-170.11% -87.96% -74.86%
Tenax Therapeutics N/A -61.54%-57.42%

Cyclerion Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Tenax Therapeutics has a consensus price target of $14.00, indicating a potential upside of 677.78%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Cyclerion Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Tenax Therapeutics
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.56

Cyclerion Therapeutics has higher revenue and earnings than Tenax Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclerion Therapeutics$2.07M8.57-$3.53M-$1.66N/A
Tenax TherapeuticsN/AN/A-$52.60M-$1.48N/A

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Tenax Therapeutics had 21 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 22 mentions for Tenax Therapeutics and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.89 beat Tenax Therapeutics' score of -0.11 indicating that Cyclerion Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cyclerion Therapeutics Very Positive
Tenax Therapeutics Neutral

Summary

Tenax Therapeutics beats Cyclerion Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Cyclerion Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYCN vs. The Competition

Export
MetricCyclerion TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$17.74M$11.80B$7.03B$13.07B
Dividend YieldN/A2.70%2.57%10.64%
P/E Ratio-2.28779.99271.2625.40
Price / Sales8.57748.58622.95105.59
Price / CashN/A89.0475.7053.27
Price / Book3.4811.6012.926.21
Net Income-$3.53M$2.77B$3.45B$347.71M
7 Day Performance6.16%0.14%1.16%1.08%
1 Month Performance3.55%0.65%2.17%1.87%
1 Year Performance60.59%145.68%62.38%20.79%

Cyclerion Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CYCN
Cyclerion Therapeutics
0.9849 of 5 stars		$3.79
-3.1%		N/A+60.6%$17.74M$2.07MN/A30
SPRO
Spero Therapeutics
1.773 of 5 stars		$1.22
-1.2%		N/A-35.6%$70.35M$54.77M5.06150
CING
Cingulate
2.9487 of 5 stars		$5.18
-0.4%		$27.33
+427.7%		+26.0%$69.78MN/AN/A20
HRTX
Heron Therapeutics
1.9425 of 5 stars		$0.35
+7.3%		$2.00
+475.5%		-74.7%$65.78M$154.90MN/A300
MNOV
MediciNova
1.8527 of 5 stars		$1.32
flat		$8.33
+531.3%		+0.0%$64.97M$410KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CYCN) was last updated on 8/16/2026 by MarketBeat.com Staff.
From Our Partners
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
The Greatest Wealth Transfer Since the Internet Boom Just Started
Wall Street forensic accountant Joel Litman - who flagged the 2008 crash months early and called the 2020 COVI...
Altimetry | Sponsoredtc pixel
"Second Wave” Hitting Iran Soon? Wall Street Issues Warning
Analysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...
TradeSmith | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel